CD274 and non-small cell lung carcinoma: Real-world OS estimates observed in Swedish patients with advanced NSCLC receiving a PD-(L)1 inhibitor-based regimen in first-line therapy were generally in line with findings reported in pivotal PD-(L)1 inhibitor clinical trials as discussed further in the text [6, 8–11].